Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: Quasi-experimental study

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Lu, Christine Y ^a   Zhang, Fang ^a   Lakoma, Matthew D ^a   Madden, Jeanne M ^a   Rusinak, Donna ^a   Penfold, Robert B ^b,c   Simon, Gregory ^b,d   Ahmedani, Brian K ^d   Clarke, Gregory ^e   Hunkeler, Enid M ^f   Waitzfelder, Beth ^g   Owen Smith, Ashli ^h   Raebel, Marsha A ^g   Rossom, Rebecca ⁱ   Coleman, Karen J ^g   Copeland, Laurel A ^j   Soumerai, Stephen B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HENRY FORD HEALTH SYSTEM   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

^f DIVISION OF RESEARCH   (United States)

^g KAISER PERMANENTE   (United States)

^h KAISER PERMANENTE   (United States)

ⁱ HEALTHPARTNERS INSTITUTE   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; DRUG APPROVAL; DRUG MONITORING; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MASS MEDIUM; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; SUICIDAL BEHAVIOR; SUICIDE; SUICIDE ATTEMPT; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DRUG LABELING; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MASS MEDIA; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; SUICIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84902603088     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3596     Document Type: Article

References (42)

1. Kaizar EE, Greenhouse JB, Seltman H, Kelleher K. Do antidepressants cause suicidality in children? A Bayesian meta-analysis. Clin Trials 2006;3:73-90; discussion 91-78.
2. Leckman JF, King RA. A developmental perspective on the controversy surrounding the use of SSRIs to treat pediatric depression. Am J Psychiatry 2007;164:1304-6. (Pubitemid 47461125)
3. Simon GE. The antidepressant quandary - considering suicide risk when treating adolescent depression. N Engl J Med 2006;355:2722-3. (Pubitemid 46021508)
4. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-9. (Pubitemid 43345358)
5. Olfson M, Marcus SC. A case-control study of antidepressants and attempted suicide during early phase treatment of major depressive episodes. J Clin Psychiatry 2008;69:425-32. (Pubitemid 351549396)
6. Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C, Miller M, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry 2010;67:497-506.
7. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163:41-7.
8. Baldessarini RJ, Pompili M, Tondo L. Suicidal risk in antidepressant drug trials. Arch Gen Psychiatry 2006;63:246-8. (Pubitemid 43345347)
9. Klein DF. The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children. Neuropsychopharmacology 2006;31:689-99.
10. Barry CL, Busch SH. News coverage of FDA warnings on pediatric antidepressant use and suicidality. Pediatrics 2010;125:88-95.
11. Harris G. FDA links drugs to being suicidal. New York Times 2004 Sep 14.
12. Vedantam S. FDA confirms antidepressants raise children's suicide risk. Washington Post 2004 Sep 14.
13. National Institute of Mental Health. Suicide in the US: statistics and prevention. 2013. www.nimh.nih.gov/health/publications/suicide-in-the-us- statistics-and-prevention/index.shtml.
14. Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012;61:1-162.
15. Gibbons RD, Mann JJ. Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned? Drug Saf 2011;34:375-95.
16. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-20. (Pubitemid 39079667)
17. March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007;64:1132-43.
18. Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:580-7.
19. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292:338-43. (Pubitemid 38944257)
20. FDA. Background briefing information. Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and Pediatric Advisory Committee. 2004. www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1.htm.
21. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007;164:884-91. (Pubitemid 46972903)
22. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009;66:633-9.
23. Busch SH, Frank RG, Leslie DL, Martin A, Rosenheck RA, Martin EG, et al. Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? Psychiatr Serv 2010;61:11-16.
24. Pamer CA, Hammad TA, Wu YT, Kaplan S, Rochester G, Governale L, et al. Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. Pharmacoepidemiol Drug Saf 2010;19:158-74.
25. Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2007;164:1198-205. (Pubitemid 47292408)
26. Morrato EH, Libby AM, Orton HD, Degruy FV 3rd, Brent DA, Allen R, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008;165:42-50. (Pubitemid 351704551)
27. Andrade SE, Raebel MA, Boudreau D, Davis RL, Haffenreffer K, Pawloski PA, et al. Health maintenance organizations/health plans. In: Strom BL, Kimel SE, Hennessy S, eds. Pharmacoepidemiology. 5th ed. Wiley-Blackwell, 2012:163-88.
28. Hornbrook MC, Hart G, Ellis JL, Bachman DJ, Ansell G, Greene SM, et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr 2005:12-25.
29. Wagner EH, Greene SM, Hart G, Field TS, Fletcher S, Geiger AM, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr 2005:3-11.
30. Crosby AE, Han B, Ortega LAG, Parks SE, Gfoerer J. Suicidal thoughts and behaviors among adults aged ≥18 years-United States, 2008-2009. MMWR Surveill Summ 2011;60(SS-13).
31. Townsend L, Walkup JT, Crystal S, Olfson M. A systematic review of validated methods for identifying depression using administrative data. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):163-73.
32. Spettell CM, Wall TC, Allison J, Calhoun J, Kobylinski R, Fargason R, et al. Identifying physician-recognized depression from administrative data: consequences for quality measurement. Health Serv Res 2003;38:1081-102. (Pubitemid 37048301)
33. Patrick AR, Miller M, Barber CW, Wang PS, Canning CF, Schneeweiss S. Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded. Pharmacoepidemiol Drug Saf 2010;19:1263-75.
34. Lu CY, Stewart C, Ahmed AT, Ahmedani BK, Coleman K, Copeland LA, et al. How complete are E-codes in commercial plan claims databases? Pharmacoepidemiol Drug Saf 2014;23:218-20.
35. Spiller HA, Appana S, Brock GN. Epidemiological trends of suicide and attempted suicide by poisoning in the US: 2000-2008. Leg Med (Tokyo) 2010;12:177-83.
36. Ting SA, Sullivan AF, Boudreaux ED, Miller I, Camargo CA Jr. Trends in US emergency department visits for attempted suicide and self-inflicted injury, 1993-2008. Gen Hosp Psychiatry 2012;34:557-65.
37. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299-309. (Pubitemid 34989269)
38. Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J Clin Epidemiol 2009;62:143-8.
39. FDA. Questions and answers on antidepressant use in children, adolescents, and adults: May, 2007. www.fda.gov/Drugs/DrugSafety/ InformationbyDrugClass/ucm096321.htm.
40. Centers for Disease Control and Prevention. Suicide among adults aged 35-64 years - United States, 1999-2010. MMWR Morb Mortal Wkly Rep 2013;62:321-5.
41. Soumerai SB, Ross-Degnan D, Kahn JS. Effects of professional and media warnings about the association between aspirin use in children and Reye's syndrome. Milbank Q 1992;70:155-82.
42. Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference. Houghton Mifflin, 2002.